Los Angeles – October 12, 2026 -- TED patients with pre-existing hearing loss were more than 60% less likely to suffer a further hearing decline when teprotumumab (TEPEZZA) infusions were spaced six weeks apart instead of the standard three, according to a retrospective study presented at the ASOPRS 57th Annual Fall Scientific Symposium.